Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
EHA 2021 movers – more fallers than risers
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
Early Morphic data hint at a threat to Entyvio
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Upcoming events – Protagonist and Pfizer target rare diseases
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Protagonist will need more than perseverance to play in bowel disease
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
